期刊文献+

TTF-1、NapsinA、CK7、P63和CK5/6在肺癌活检组织学分型诊断的价值 被引量:1

Diagnostic Value of TTF-1, Napsin A, CK7, P63 and CK5/6 in Lung Cancer Biopsy Tissue Typing
下载PDF
导出
摘要 目的分析在肺癌活检的组织学分型诊断中应用CK5/6、TTF-1、P63、Napsin A以及CK7的价值。方法选在我院进行支气管镜检与肺穿刺活检患者200例,其中195例患者为原发性肺癌,5例患者为转移性腺癌,回顾分析患者的临床资料。结果在AC患者中,TTF-1、Napsin A、CK7占比明显要比SCC、SCLC占比大,经过对比,差异有统计学意义,P<0.05;在SCC患者中P63、CK5/6占比明显要比AC、SCLC大,差异有统计学意义,P<0.05;AC、SCC患者中CK7、CK5/6占比明显要比SCLC大,差异有统计学意义,P<0.05。结论在肺癌活检的组织学分型诊断中联合应用CK5/6、TTF-1、P63、Napsin A以及CK7,能够给临床治疗提供参考。 Objective To analyze the value of CK5/6, TW-1, P63, Napsin A and CK7 in the histological diagnosis of lung cancer biopsy. Methods 200 cases of bronchoscopy and lung biopsy.were selected in our hospital, of which 195 cases were primary lung cancer and 5 cases were metastatic adenocarcinoma. The clinical data of the patients were retrospectively analyzed. Results In AC patients, the proportion of TTF-1, Napsin A and CK7 was significantly higher than that of SCC and SCLC. After comparison, the difference was statistically significant, P 〈 0.05; In SCC patients, the proportion of P63 and CK5/6 was significantly higher than that of AC and SCLC, and the difference was statistically significant, P 〈 0.05; The proportion of CK7 and CK5/6 in patients with AC and SCC was significantly higher than that of SCLC, and the difference was statistically significant, P 〈 0.05. Conclusion The combination of CK5/6, TTF-1, P63, Napsin A and CK7 in the diagnosis of lung cancer biopsy can provide reference for clinical treatment.
作者 曹丽芳 何春燕 CAO Lifang;HE Chunyan(Department of Pathology, Guangdong Provincial Nongken Central Hospital, Zhanjiang Guangdong 524000, Chin)
出处 《中国继续医学教育》 2017年第26期57-58,共2页 China Continuing Medical Education
关键词 免疫组化 肺癌活检 组织学分型 immunnhistochemistry biopsy of lung cancer histological typing
  • 相关文献

参考文献8

二级参考文献54

  • 1苑喜明,赵琦,钱永红.恶性肿瘤致心包积液67例临床分析[J].肿瘤研究与临床,2007,19(z1). 被引量:3
  • 2Scagliotti G, Pastorino U, Vansteenkiste J, et al. A phase Ⅲ randomized study of surgery alone or surgery plus preoperative gemcitabine - cisplatin in early-stage non - small cell lung cancer ( NSCLC ) : follow-up data of Ch.E. S. T [ J ]. J Clin Oncol,2008,26 (S) :7508.
  • 3Pisters K,Vallieres E,Bunn PA,et al. S9900:Surgery alone or surgery plus induction ( ind ) paclitaxel/carboplatin ( PC ) chemotherapy in early stage non-small cell lung cancer (NSCLC) :Follow-up on a phase Ⅲ trial[ J]. J Clin Oncol, 2007,25(18S) :7520.
  • 4Le Chevalier T, Dunant A, Arriaggada R, et al. Long - term results of the International Adjuvant Lung Cancer Trial (IALT) evaluation adjuvant cisplatin - based chemotherapy in resected non-small cell lung cancer (NSCLC) [J]. J Clin Oncol,2008,26 (S) :7507.
  • 5Taso MS, Zhu C, Ding K, et al. A 15-gene expression signature prognostic for survival prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR. 10 patient [ J ]. J Clin Oncol,2008,26(S) :7510.
  • 6EI-Shenshawy HM, Fathy A, Eteba S, et al. Sequential chemoradiotherapy versus concurrent chemoradiotherapy PLUS comsodidation chenmotherapy in unresectable stage Ⅲ non-small cell lung cancer[ J]. J Clin Oncol,2008,26(S) :8509.
  • 7Mina LA, Neeubauer MA, Ansafi RH, et al. Phase III trial of cisplatin (P) plus etoposid (E) plus concurrent chest radia- tion (CRT) in patient (PTS) with or without consolidation docetaxel(D) in patients(pts) with inoperable stage Ⅲ non - small cem ung cancer(NSCLC) :HOU LUN 01-24/USO- 023-Updated results[ J]. J Clin Oncol,2008,26(S) :7519.
  • 8andler AB, Gray R, Brahmer J, et al. Pactiltaxal-Carboplatin Alone or with Bevacizurnab for Non-Small-Cell lung Cancer [ J]. New England Journal of Medcine ,2006,355:2542-2250.
  • 9Hida T, Okamoto I, Kashii T, et al. Randomized phase Ⅲ study of platinum - doublet chemotherapy followed by gefitinib versus continued platinum-doublet chenotherapy in patient (pts) with advanced non-small cell lung cancer (NSCLC) :Results of West Japan Thoracic Oncology Group.trial ( WJTOG ) [ J ]. J Clin Oncol,2008,26 ( S ) : 8013.
  • 10Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomizd trial of docetaxel versus best supportive care in patieents with non-small-cell lung cancer previously teeated with platinu-based chemotherapy[J]. J Clin Oncol,2000,18:2095.

共引文献42

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部